A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Ricolinostat (Primary) ; Bevacizumab; Paclitaxel
- Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 27 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 17 Aug 2016 Status changed from not yet recruiting to recruiting.